- Alikhan A , Sayed C , Alavi A , et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: Part I: diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol . 2019;81(1):76–90. doi:10.1016/j.jaad.2019.02.067.
- Vinkel C , Thomsen SF. Hidradenitis suppurativa: causes, features, and current treatments. J Clin Aesthet Dermatol . 2018;11(10):17–23.
- Napolitano M , Megna M , Timoshchuk EA , et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clin Cosmet Investig Dermatol . 2017;10:105–115. doi:10.2147/CCID.S111019.
- Zouboulis CC , Desai N , Emtestam L , et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol . 2015;29(4):619–644. doi:10.1111/jdv.12966.
- Scuderi N , Monfrecola A , Dessy LA , et al. Medical and surgical treatment of hidradenitis suppurativa: a review. Skin Appendage Disord . 2017;3(2):95–110. doi:10.1159/000462979.
- Ingram JR , Collier F , Brown D , et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol . 2019;180(5):1009–1017. doi:10.1111/bjd.17537.
- Zouboulis CC , Tzellos T , Kyrgidis A , et al ; European Hidradenitis Suppurativa Foundation Investigator Group . Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol . 2017;177(5):1401–1409. doi:10.1111/bjd.15748.
- Sartorius K , Emtestam L , Jemec GB , et al. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol . 2009;161(4):831–839. doi:10.1111/j.1365-2133.2009.09198.x.
- Kimball AB , Sobell JM , Zouboulis CC , et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol . 2016;30(6):989–994. doi:10.1111/jdv.13216.
- Dauden E , Lazaro P , Aguilar MD , et al. Recommendations for the management of comorbidity in hidradenitis suppurativa. J Eur Acad Dermatol Venereol . 2018;32(1):129–144. doi:10.1111/jdv.14517.
- Jemec GB , Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol . 1998;39(6):971–974. doi:10.1016/s0190-9622(98)70272-5.
- Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol . 1983;22(5):325–328. doi:10.1111/j.1365-4362.1983.tb02150.x.
- Danesh MJ , Kimball AB. Pyrithione zinc as a general management strategy for hidradenitis suppurativa. J Am Acad Dermatol . 2015;73(5):e175doi:10.1016/j.jaad.2015.07.026.
- Boer J , Jemec GB. Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa. Clin Exp Dermatol . 2010;35(1):36–40. doi:10.1111/j.1365-2230.2009.03377.
- Mahmoud BH , Tierney E , Hexsel CL , et al. Prospective controlled clinical and histopathologic study of hidradenitis suppurativa treated with the longpulsed neodymium:yttrium-aluminium-garnet laser. J Am Acad Dermatol . 2010;62(4):637–645. doi:10.1016/j.jaad.2009.07.048.
- Riis PT , Boer J , Prens EP , et al. Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): a case series. J Am Acad Dermatol . 2016;75(6):1151–1155. doi:10.1016/j.jaad.2016.06.049.
- Fischer AH , Haskin A , Okoye GA. Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa. J Am Acad Dermatol . 2017;76(2):309–313.e302. doi:10.1016/j.jaad.2016.08.001.
- Alavi A , Kirsner RS. Local wound care and topical management of hidradenitis suppurativa. J Am Acad Dermatol . 2015;73(5 Suppl 1):S55–S61. doi:10.1016/j.jaad.2015.07.048.
- Alikhan A , Sayed C , Alavi A , et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: topical, intralesional, and systemic medical management. J Am Acad Dermatol . 2019;81(1):91–101. doi:10.1016/j.jaad.2019.02.068.
- Jemec GBE , Revuz J , Leyden J. Hidradenitis Suppurativa . Berlin, Germany: Springer; 2006:138–140.
- Firooz A , Tehranchi-Nia Z , Ahmed AR. Benefits and risks of intralesional corticosteroid injection in the treatment of dermatological diseases. Clin Exp Dermatol . 1995;20(5):363–370. doi:10.1111/j.1365-2230.1995.tb01351.x.
- Vural S , Gündoğdu M , Akay BN , et al. Hidradenitis suppurativa: clinical characteristics and determinants of treatment efficacy. Dermatol Ther . 2019;32(5):e13003. doi:10.1111/dth.13003.
- van der Zee HH , Boer J , Prens EP , et al. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology (Basel) . 2009;219(2):143–147. doi:10.1159/000228337.
- Gener G , Canoui-Poitrine F , Revuz JE , et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology . 2009;219(2):148–154. doi:10.1159/000228334.
- Smieja M. Current indications for the use of clindamycin: a critical review. Can J Infect Dis . 1998;9(1):22–28. doi:10.1155/1998/538090.
- Yazdanyar S , Boer J , Ingvarsson G , et al. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology (Basel) . 2011;222(4):342–346. doi:10.1159/000329023.
- Join-Lambert O , Coignard H , Jais JP , et al. Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. Dermatology (Basel) . 2011;222(1):49–58. doi:10.1159/000321716.
- Mortimer PS , Dawber RP , Gales MA , Moore RA. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol . 1986;115(3):263–268. doi:10.1111/j.1365-2133.1986.tb05740.
- Sawers RS , Randall VA , Ebling FJ. Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy. Br J Dermatol . 1986;115(3):269–274. doi:10.1111/j.1365-2133.1986.tb05741.
- Lee A , Fischer G. A case series of 20 women with hidradenitis suppurativa treated with spironolactone. Australas J Dermatol . 2015;56(3):192–196. doi:10.1111/ajd.12362.
- Verdolini R , Clayton N , Smith A , Alwash N , Mannello B. Metformin for the treatment of hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venereol . 2013;27(9):1101–1108. doi:10.1111/j.1468-3083.2012.04668.
- Khandalavala BN , Do MV. Finasteride in hidradenitis suppurativa: a “male” therapy for a predominantly “female” disease. J Clin Aesthet Dermatol . 2016;9(6):44–50.
- Randhawa HK , Hamilton J , Pope E. Finasteride for the treatment of hidradenitis suppurativa in children and adolescents. JAMA Dermatol . 2013;149(6):732–735. doi:10.1001/jamadermatol.2013.2874.
- Joseph MA , Jayaseelan E , Ganapathi B , Stephen J. Hidradenitis suppurativa treated with finasteride. J Dermatolog Treat . 2005;16(2):75–78. doi:10.1080/09546630510031403.
- Wiseman MC. Hidradenitis suppurativa: a review. Dermatol Ther . 2004;17(1):50–54. doi:10.1111/j.1396-0296.2004.04007.
- Danto JL. Preliminary studies of the effect of hydrocortisone on hidradenitis suppurativa. J Invest Dermatol . 1958;31(6):299–300. doi:10.1038/jid.1958.124.
- Camisa C , Sexton C , Friedman C. Treatment of hidradenitis suppurativa with combination hypothalamic-pituitary-ovarian and adrenal suppression. A case report. J Reprod Med . 1989;34(8):543–546.
- Wong D , Walsh S , Alhusayen R. Low-dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa. J Am Acad Dermatol . 2016;75(5):1059–1062. doi:10.1016/j.jaad.2016.06.001.
- Reddy S , Orenstein LAV , Strunk A , Garg A. Incidence of long-term opioid use among opioid-naive patients with hidradenitis suppurativa in the United States. JAMA Dermatol . 2019;155(11):1284–1290. doi:10.1001/jamadermatol.2019.2610.
- Saunte DM , Boer J , Stratigos A , et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol . 2015;173(6):1546–1549. doi:10.1111/bjd.14038.
- Hendricks AJ , Hsiao JL , Lowes MA , et al. A comparison of international management guidelines for hidradenitis suppurativa. Dermatology (Basel) . 2019;:1–16.
Hidradenitis suppurativa for the nondermatology clinician
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.